首页> 外文期刊>Archives of surgery. >Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator in colon cancer.
【24h】

Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator in colon cancer.

机译:微卫星不稳定性和淋巴细胞浸润的结合作为结肠癌的预后指标。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Microsatellite instability (MSI) is a genetic aberration associated with less aggressive tumor biology. Some tumors with MSI also have lymphocytic infiltrate (LI), which suggests a heightened immune response against the tumor. OBJECTIVE: To evaluate the combined prognostic significance of MSI and LI in a colon cancer population. DESIGN: Colon cancers were prospectively evaluated for MSI by assessing 11 satellite markers and were classified as MSI+ if 2 or more satellite markers displayed instability. Tumors were classified as LI+ if at least 5 lymphocytes were observed per 10 high-power fields. SETTING: Community hospital system. PATIENTS: Individuals undergoing definitive surgery for colon cancer. MAIN OUTCOME MEASURES: Overall and disease-free survival were compared according to combined MSI and LI status. RESULTS: In 150 patients, tumors were classified as follows: 95 were MSI-/LI-, 9 were MSI-/LI+, 30 were MSI+/LI-, and 16 were MSI+/LI+. Median follow-up was 40.6 months. Five-year disease-free survival was 56.7% for patients with MSI-/LI- tumors and 88.9% for those with MSI+/LI+ tumors (P = .01). Patients with MSI+/LI- and MSI-/LI+ tumors had 5-year survival of 75.4% and 75.0%, respectively. CONCLUSIONS: Patients with colon cancer and MSI-/LI- tumors have worse disease-free survival rate regardless of stage at diagnosis. Patients exhibiting both MSI+ and LI+ tumors have more favorable disease-free survival rates. Both MSI and LI show promise as a combined prognostic marker and with further study may prove to be particularly useful in selecting patients with stage II disease for adjunctive therapy.
机译:背景:微卫星不稳定性(MSI)是与侵略性较低的肿瘤生物学相关的遗传畸变。一些患有MSI的肿瘤也有淋巴细胞浸润(LI),这表明针对肿瘤的免疫反应增强。目的:评估MSI和LI在结肠癌人群中的联合预后意义。设计:通过评估11个卫星标记对结肠癌进行前瞻性评估,如果2个或多个卫星标记显示不稳定,则将其分类为MSI +。如果每10个高倍视野至少观察到5个淋巴细胞,则将肿瘤分类为LI +。单位:社区医院系统。患者:接受结肠癌彻底手术的患者。主要观察指标:根据合并的MSI和LI状态比较总体生存期和无疾病生存期。结果:150例患者的肿瘤分类如下:MSI- / LI- 95例,MSI- / LI + 9例,MSI + / LI- 30例,MSI + / LI + 16例。中位随访时间为40.6个月。 MSI- / LI-肿瘤患者的五年无病生存率为56.7%,MSI + / LI +肿瘤患者为88.9%(P = .01)。 MSI + / LI-和MSI- / LI +肿瘤患者的5年生存率分别为75.4%和75.0%。结论:结肠癌和MSI- / LI-肿瘤患者的无病生存率较差,无论其诊断阶段如何。同时显示MSI +和LI +肿瘤的患者的无病生存率更高。 MSI和LI均显示出有希望作为联合预后标志物,并且经过进一步的研究可能被证明在选择II期疾病的辅助治疗患者中特别有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号